REMEDIUM

This article presents the history and structure of the school of clinical trials monitors in Russia, the reasons for its opening in 2011, as well as the results of a survey of graduates. The authors discuss in detail what tasks they faced in creating a high-quality, modern, interactive educational program that is sustainable in the long term. Shows the important role of collaboration between academic institutions and business companies directly involved in clinical research on a daily basis. The structure of the course is presented, as well as teaching materials and electronic systems and technologies are used. Separately, the experience of operating a school during the COVID-19 pandemic is given, an analysis of the course functioning in fully online format, the positive and negative aspects of this approach. The second part of the article presents the results of a survey of graduates of the course for 9 years: from their satisfaction with training, to their further professional career (a total of 8 questions). In conclusion, the authors present their personal attitude to this educational project.

Неблагоприятная эпидемическая обстановка и связанные с ней государственные расходы на медико-фармацев- тическую сферу придали дополнительный импульс росту российского фармрынка уже в первые месяцы 2020 г. Основными драйверами этого роста в средне- и долгосрочной перспективе по-прежнему останутся государственные инвестиции в закупки фармацевтической и медицинской продукции, а также реализация стратегии «Фарма-2030». Принятая еще в апреле 2019 г. данная стратегия предусматривает рост расходов на здравоохранение, дальнейшее импортозамещение, локализацию производства, а также развитие электронной коммерции в фармацевтическом ретейле.

2020, with all its challenges, has been a test of strength for the distributor chains. After all, it was them on whom uninterrupted provision of population with medicines largely depended: timely supply of drugs to the pharmacies, dealing with manufacturers to bridge emerging deficiencies - these and other significant challenges have once again confirmed that distributors constitute an integral part of the product supply chain, and their significance is very high.

Acute cerebrovascular accidents (ACVAs) rank among the leaders in the morbidity pattern of the adult population. The annual incidence of strokes per 1000 population in different countries around the world is 1.3 to 7.4 cases [1]. In addition, acute ischemic accidents (ischemic stroke, cerebral infarction) account for about 80% of all strokes in Russia [2]. The search for effective pharmacotherapy for such patients is one of the major challenges for modern medicine.

Железодефицитная анемия (ЖДА) - патологическое состояние, характеризующееся нарушением синтеза гемоглобина в результате дефицита железа. Наиболее часто ЖДА встречается у беременных женщин и кормящих матерей, негативно влияя как на их здоровье, так и на здоровье плода и новорожденного.О роли железа в организме, проблемах, связанных с его дефицитом, клинических проявлениях ЖДА и современных подходах к ее лечению мы решили поговорить с Верой Николаевной Прилепской, заместителем директора по научной работе, заведующей научно-поликлиническим отделением ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова» Министерства здравоохранения РФ, д.м.н., профессором.

The rapid spread of diabetes mellitus (DM) is one of the global health challenges around the world. In Russia, the number of registered patients reached 5.1 million in 2020 [1]. Today, it does not raise doubts that achieving good glycaemic control prevents or significantly reduces the risk of development and progression of chronic complications in patients with diabetes. With advances in technology, “smart” glucometers have been launched, significantly expanding options in diabetes management [2].

Introduction. The COVID-19 pandemic caused an outbreak of viral lung infections with severe acute respiratory syndrome complicated with acute respiratory failure. Despite the fact that the pandemic has a lengthened run, none of the therapeutic approaches have proved to be sufficiently effective according to the evidence-based criteria. We consider the use of surfactant therapy in patients with severe viral pneumonia and acute respiratory distress syndrome (ARDS) as one of the possible methods for treating COVID-19 related pneumonia. Objective. To prove the clinical efficacy and safety of orally inhaled Surfactant-BL, an authorized drug, in the combination therapy of COVID-19 related ARDS.Materials and methods. A total of 38 patients with COVID-19 related severe pneumonia and ARDS were enrolled in the study. Of these, 20 patients received the standard therapy in accordance with the temporary guidelines for the prevention, diagnosis and treatment of the novel coronavirus infection (COVID-19) of the Ministry of Health of the Russian Federation, version 9. And 18 patients received the surfactant therapy in addition to the standard therapy. Surfactant-BL was used in accordance with the instructions on how to administer the drug for the indication - prevention of the development of acute respiratory distress syndrome. A step-by-step approach to the build-up of the respiratory therapy aggressiveness was used to manage hypoxia. We used oxygen inhalation via a face mask with an oxygen inflow of 5-15 l/min, high- flow oxygen therapy via nasal cannulas using Airvo 2 devices, non-invasive lung ventilation, invasive lung ventilation in accordance with the principles of protective mechanical ventilation.

In recent years, technology and innovation have moved in leaps and bounds, changing all sectors including healthcare and pharmaceutics. The use of Big Data and process automation are driving rapid progress. The most modern approaches are being introduced into pharmacies and pharmaceutical enterprises even today.

Law enforcement practice in the sphere of drug advertising continues to be one of the most challenging and controversial regulatory areas. Market players develop industry guidelines, companies enact by-laws to deal with advertising materials and risk mitigation strategies. However, life always makes adjustments even to the application of well-established algorithms. Some approaches of the law enforcers get deeper roots, while others grow more and more detailed, which often needs to be reflected in the internal policies of advertisers and advertising distributors. The antimonopoly authority practice was no exception in 2020. In this regard, the article will provide a brief review of the key, in our opinion, decisions of law enforcement authorities and summarize the old and new interpretations.

С 1 января 2021 г. вступил в силу новый перечень ЖНВЛП, который пополнился 25 наименованиями, среди них - один из немногих препаратов для патогенетического лечения спинальной мышечной атрофии (СМА) нусинерсен. Это означает, что теперь он будет закупаться государством по фиксированной предельной отпускной цене, равной5 138 690 78 руб. за упаковку. Такую сумму производитель препарата компания Янссен заявила к регистрации на основании минимальной референтной цены, что на четверть ниже средней цены государственных закупок в 2020 г. О значимости этого события мы поговорили с экспертами.

Производство медицинской продукции за 2020 год Фармацевтическая реклама ЛП и БАД в российских СМИ в январе 2021 года ТОП-20 крупнейших рекламодателей и рекламируемых марок ЛП и БАД в Российских СМИ* в январе 2021 года